EQT Corporation Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? EQT Corporation Common Stock trades at $52.5 (market cap $34.05B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: EQT Corporation Common Stock is far larger — about 3.8× Kymera Therapeutics Inc. Common Stock's market cap, and EQT Corporation Common Stock pays a 1.21% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EQT Corporation Common Stock for 1 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| EQT | KYMR | |
|---|---|---|
Market Cap | $34.05B | $8.87B |
Volume | 4,662,584 | 779,107 |
Sector | Energy | Health |
52-Week High | $67.93 | $127.31 |
52-Week Low | $48.56 | $55.80 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $39.59B | $8.26B |
Dividend Yield | 1.21% | — |
Signals from Pluang's Aura AI — not financial advice
EQT trades at $54.43, up 2.27% today, with a bullish technical outlook and strong analyst consensus. The stock benefits from robust profitability, with a net income margin of 28.61% and a P/E ratio of 12.63. Recent news highlights a dividend increase and positive natural gas market tailwinds, while institutional buying activity supports sentiment. Earnings have mostly beaten expectations, with Q3 2026 results pending.
The outlook for EQT is positive, driven by operational efficiency, favorable natural gas demand, and a strong balance sheet. Risks include commodity price volatility and execution of growth plans. With a consensus price target of $70.33 implying significant upside, the stock presents a compelling opportunity for investors seeking exposure to the energy sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EQT produces and transports natural gas, with production and midstream operations in the Appalachian Basin. Its operations are concentrated in Pennsylvania, West Virginia, and Ohio.
Read more on EQT →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →